and the extension of its cash runway to 2028.
• Capital increase for a total gross amount of €3 million through the issue of a total number of 1,477,934 new ordinary shares, at a price of €2.04 per share
• Participation of all of the Company’s directors and of its Chief Executive Officer, as well as of a limited number of historical investors
• €4 million increase of the shareholder loan agreement signed with Vester Finance on April 21, 2026, repayable in new shares or in cash
• Cash runway extended to Q1 2028 thanks to this financing transaction combined with costi reductions. Objective of bridging to the $20m milestone payment for the marketing authorization approval of BC Lispro in China, providing financial visibility until 2029
